Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Eukaryotic Gene Expression
Fator do impacto: 1.841 FI de cinco anos: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN Imprimir: 1045-4403
ISSN On-line: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.2017019539
pages 355-361

miRNA in Hepatocellular Carcinoma: Pathogenesis and Therapeutic Approaches

Muhammad Imran Qadir
Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Bosan Road, Multan, Pakistan
Samana Zahra Rizvi
Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan

RESUMO

Hepatocellular carcinoma (HCC) is a worldwide disease. Because therapeutic measures are ineffective, HCC currently has a poor prognosis. The main causes of HCCs are alcoholism, hepatitis, and metabolic syndrome. Normally hygieinic studies revealed that there is lower survival rate of HCC. MicroRNAs (miRNAs) consist of short noncoding sequences of RNA (20 to 24 nucleotides), which posttranscriptionally regulate the expression of the protein coding genes. MicroRNAs have been proposed to be prospective therapeutic molecules and targets. For testing miRNA-based therapies, HCC is a remarkable model because it may be targeted by delivery of oligonucleotides. Current studies show a beginning for analyzing the therapeutic prospects of miRNAs or anti–miRNAs. Generally, antitumor activity of miRNAs has been observed.